
Angel Perez-Sempere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2488276/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions. Patient, 2021, 14, 241-248.	1.1	2
2	Contribution of Gray Matter Atrophy and White Matter Damage to Cognitive Impairment in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients. Diagnostics, 2021, 11, 578.	1.3	5
3	Regret and Therapeutic Decisions in Multiple Sclerosis Care: Literature Review and Research Protocol. Frontiers in Neurology, 2021, 12, 675520.	1.1	5
4	SARS-CoV-2 Infection in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	27
5	Realâ€world experience of ocrelizumab in multiple sclerosis in a Spanish population. Annals of Clinical and Translational Neurology, 2021, 8, 385-394.	1.7	23
6	Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. PLoS ONE, 2021, 16, e0261050.	1.1	4
7	Understanding the Deterioration of Gait, Postural Control, Lower Limb Strength and Perceived Fatigue Across the Disability Spectrum of People with Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1385.	1.0	7
8	A general presentation on how to carry out a <scp>CHARMS</scp> analysis for prognostic multivariate models. Statistics in Medicine, 2020, 39, 3207-3225.	0.8	2
9	Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?. Multiple Sclerosis and Related Disorders, 2020, 45, 102354.	0.9	4
10	Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient's Perspective. Neurology and Therapy, 2020, 9, 173-179.	1.4	9
11	Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. Journal of Neurology, 2019, 266, 2512-2517.	1.8	17
12	Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain. Multiple Sclerosis and Related Disorders, 2019, 33, 78-81.	0.9	8
13	Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731983522.	0.5	3
14	Adaptación cultural y validación al español de España del MSTCQ© (Multiple Sclerosis Treatment) Tj ETQq	0 8.9 rgBT	Qverlock 1
15	Observational Study of Switching from Natalizumab to Immunomodulatory Drugs. European Neurology, 2017, 77, 130-136.	0.6	13
16	Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open, 2017, 7, e014433.	0.8	28

17	Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS. Patient Preference and Adherence, 2017, Volume 11, 175-180.	0.8	11
18	Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS). Frontiers in Neurology, 2017, 8, 65.	1.1	42

ANGEL PEREZ-SEMPERE

#	Article	IF	CITATIONS
19	Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. Frontiers in Neurology, 2017, 8, 430.	1.1	16
20	Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS). BMC Neurology, 2016, 16, 58.	0.8	41
21	Rescue Therapy Using Rituximab for Multiple Sclerosis. Clinical Neuropharmacology, 2016, 39, 178-181.	0.2	16
22	Eyelid myokymia in patients with migraine taking topiramate. Acta Neurologica Scandinavica, 2015, 132, 143-146.	1.0	9
23	Folletos de información educativa en migraña: satisfacción percibida en un grupode pacientes. NeurologÃa, 2015, 30, 472-478.	0.3	5
24	Bibliometric profile of the global scientific research on multiple sclerosis (2003–2012). Multiple Sclerosis Journal, 2015, 21, 235-245.	1.4	24
25	Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. Expert Opinion on Drug Safety, 2014, 13, 1287-1289.	1.0	6
26	Mutation Prevalence of Cerebral Cavernous Malformation Genes in Spanish Patients. PLoS ONE, 2014, 9, e86286.	1.1	29
27	Response to Immunotherapy in CLIPPERS: Clinical, MRI, and MRS Followâ€Up. Journal of Neuroimaging, 2013, 23, 254-255.	1.0	26
28	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	1.4	35
29	Oral BG-12 in Multiple Sclerosis. New England Journal of Medicine, 2013, 368, 1652-1653.	13.9	3
30	Benign hereditary chorea: Clinical features and long-term follow-up in a Spanish family. Parkinsonism and Related Disorders, 2013, 19, 394-396.	1.1	9
31	Linfoma cerebral primario con remisión espontánea. NeurologÃa, 2013, 28, 123-126.	0.3	5
32	Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1338-1339.	0.9	14
33	Switching from natalizumab to fingolimod: an observational study. Acta Neurologica Scandinavica, 2013, 128, e6-e10.	1.0	52
34	Rebound of disease activity during pregnancy after withdrawal of fingolimod. European Journal of Neurology, 2013, 20, e109-10.	1.7	52
35	Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese Data. Neuroepidemiology, 2012, 38, 209-216.	1.1	18
36	Bilateral optic neuritis in a 26-year-old man with common variable immunodeficiency: a case report. Journal of Medical Case Reports, 2011, 5, 319.	0.4	9

#	Article	IF	CITATIONS
37	Bilateral akinetic seizures: A clinical and electroencephalographic description. Epilepsia, 2010, 51, 2108-2115.	2.6	4
38	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Multiple Sclerosis Journal, 2009, 15, 1303-1310.	1.4	57
39	Reversible Dementia Secondary to Topiramate. Clinical Neuropharmacology, 2008, 31, 62.	0.2	8
40	Clinical characteristics associated with psychosocial functioning among patients with uncomplicated epilepsy in Spain. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 195-203.	0.9	16
41	Neuroimaging in the Evaluation of Patients with Non-Acute Headache. Cephalalgia, 2005, 25, 30-35.	1.8	110
42	Primary Cough Headache Responsive to Topiramate. Cephalalgia, 2005, 25, 627-628.	1.8	18
43	Cerebral Ischemia: New Risk Factors. Cerebrovascular Diseases, 2004, 17, 43-50.	0.8	32
44	Prevalence of Parkinson's disease in Cantalejo, Spain: A door-to-door survey. Movement Disorders, 2002, 17, 242-249.	2.2	68
45	Generalized spike-and-wave patterns in children: clinical correlates. Pediatric Neurology, 2000, 22, 23-28.	1.0	3
46	Etiopathogenesis of Transient Ischemic Attacks and Minor Ischemic Strokes. Stroke, 1998, 29, 40-45.	1.0	24
47	Postural Myoclonus Induced by Phenytoin. Clinical Neuropharmacology, 1996, 19, 536-538.	0.2	17
48	Pseudopheochromocytoma in a Patient with Parkinson's Disease. Annals of Pharmacotherapy, 1996, 30, 546-546.	0.9	13
49	Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 1996, 3, 397-398.	1.7	2
50	Headache of recent onset in adults: a prospective population-based study. Acta Neurologica Scandinavica, 1996, 94, 67-70.	1.0	29
51	Incidence of Transient Ischemic Attacks and Minor Ischemic Strokes in Segovia, Spain. Stroke, 1996, 27, 667-671.	1.0	42
52	Aggravation of Parkinsonian Tremor by Cisapride. Clinical Neuropharmacology, 1995, 18, 76-78.	0.2	24
53	Peripheral iron metabolism in patients with focal cerebral ischemia. European Journal of Neurology, 1995, 2, 107-109.	1.7	2
54	Serum levels of nitrates in focal cerebral ischemia. European Journal of Neurology, 1995, 2, 225-227.	1.7	3

ANGEL PEREZ-SEMPERE

#	Article	IF	CITATIONS
55	Parkinsonism induced by amlodipine. Movement Disorders, 1995, 10, 115-116.	2.2	27
56	Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivity. Movement Disorders, 1995, 10, 643-649.	2.2	74
57	Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin. Journal of Neurology, 1995, 242, 114-115.	1.8	19
58	Efficacy of Intranasal Apomorphine in Parkinson's Disease. Journal of Pharmacy Technology, 1995, 11, 226-228.	0.5	1
59	Guillain-Barr6 Syndrome After Acute Myocardial Infarction Treated With Anistreplase. Chest, 1994, 105, 1301-1302.	0.4	10
60	Non-ischaemic causes of transient ischaemic attacks and minor strokes Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 659-660.	0.9	0
61	Parkinsonism and tardive dyskinesia after chronic use of clebopride. Movement Disorders, 1994, 9, 114-115.	2.2	14
62	Acute Headache of Recent Onset and Subarachnoid Hemorrhage: A Prospective Study. Headache, 1994, 34, 172-174.	1.8	45
63	Low-Dose Sodium Valproate in the Prophylaxis of Migraine. Clinical Neuropharmacology, 1994, 17, 569-573.	0.2	12
64	Thyroxine-Induced Partial Complex Status Epilepticus. Annals of Pharmacotherapy, 1993, 27, 1139-1139.	0.9	1
65	Intravenous Midazolam Suppression of Complex Partial Status Refractory to Intravenous Phenytoin and Diazepam. Clinical Neuropharmacology, 1993, 16, 468-470.	0.2	5
66	Impotence Associated with Cinnarizine. Annals of Pharmacotherapy, 1993, 27, 370-371.	0.9	2
67	First seizure in adults: a prospective study from the emergency department. Acta Neurologica Scandinavica, 1992, 86, 134-138.	1.0	52
68	Cerebral venous thrombosis as a cause of neonatal focal clonic seizures. Journal of Neurology, 1992, 239, 294-294.	1.8	3
69	Spongiform leucoencephalopathy after inhaling heroin. Lancet, The, 1991, 338, 320.	6.3	35
70	Isolated Oculomotor Nerve Palsy due to Dural Cavernous Sinus Fistula. European Neurology, 1991, 31, 186-187.	0.6	12